Maurice Dahdaleh graduated from Westminster Medical School (Imperial College), London University and did his training in Internal Medicine and Neurology in the United Kingdom. He is a Fellow of the Royal College of Physicians, London and worked in Jordan as part-time Lecturer and later Associate Professor in Clinical Neurology at Jordan Hospital Medical School. He developed several interests in Clinical Neurology including Multiple Sclerosis, Cerebrovascular disease and Movement Disorders. He is member of many local, regional and international neurological societies and past Chair of Scientific Committee and President of the Jordanian Neuroscience Society. He served for many years as an examiner on the Jordanian Neurology Board and at present he chairs its committee. In 1994, Dr. Dahdaleh introduced beta-interferon 1a for the first time in Jordan on a patient named basis for the treatment of patients with multiple sclerosis. In addition, he pioneered the introduction of botulinum toxin in the treatment of focal dystonia and spasticity and thrombolytic therapy in management of acute stroke. From 1997, he worked in the United Kingdom as honorary Consultant Neurologist at St. Mary’s Hospital, London. He returned to Amman Jordan in 2008 as Consultant Neurologist mainly in the private sector with affiliation to Khalidi Hospital Medical Center and the Arab Medical Center, where he is devoting more time for the management of patients with multiple sclerosis. He is a member of many regional advisory boards on Multiple Sclerosis and co-authored several papers on multiple sclerosis. He is a founding member of MENACTRIMS.